Innovative financing for the elimination of hepatitis - September 2016 (London, UK)
The CDA Foundation sponsored a meeting to discuss alternative methods to finance the elimination of hepatitis by 2030. Attendees included representatives from the World Hepatitis Alliance, the World Bank, Global Fund, Viet Nam MoH, Malaysia MoH, US CDC, CHAI, Viral Hepatitis Board, PharmAccess, Pharos Global Health, Wisper Public Affairs, diagnostic companies (Abbott, Cephied, Roche), originator pharmaceutical companies (Abbvie, Gillead, Merck) and generic companies (Cadila, Ferozsons, Hetero, Strides Shasun, Mylan) . Each attendee was interviewed prior to the meeting. For a summary of the results of the survey, click here.
The outcome of the meeting was the creation of the Global Procurement (GPRO) Fund to provide affordable quality medicines and diagnostics to countries to support their elimination targets.